JP4762383B2 - Fibroblast proliferator - Google Patents
Fibroblast proliferator Download PDFInfo
- Publication number
- JP4762383B2 JP4762383B2 JP06128798A JP6128798A JP4762383B2 JP 4762383 B2 JP4762383 B2 JP 4762383B2 JP 06128798 A JP06128798 A JP 06128798A JP 6128798 A JP6128798 A JP 6128798A JP 4762383 B2 JP4762383 B2 JP 4762383B2
- Authority
- JP
- Japan
- Prior art keywords
- fibroblast
- phytoglycogen
- present
- proliferating agent
- minutes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 210000002950 fibroblast Anatomy 0.000 title claims description 25
- 229920002387 Phytoglycogen Polymers 0.000 claims description 18
- BYSGBSNPRWKUQH-UJDJLXLFSA-N glycogen Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)O1 BYSGBSNPRWKUQH-UJDJLXLFSA-N 0.000 claims description 18
- 230000002062 proliferating effect Effects 0.000 claims description 12
- 239000004480 active ingredient Substances 0.000 claims description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 239000003795 chemical substances by application Substances 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 230000035755 proliferation Effects 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 229920002527 Glycogen Polymers 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 241000482268 Zea mays subsp. mays Species 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000009759 skin aging Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000012192 staining solution Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- 229920001342 Bakelite® Polymers 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- -1 methanol and ethanol Chemical compound 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000004215 skin function Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
【０００１】
【発明の属する技術分野】
本発明は、フィトグリコーゲンを有効成分とした新規な線維芽細胞増殖剤に関する。
【０００２】
【従来の技術】
フィトグリコーゲンとは、動物の細胞内、特に肝臓や筋肉に多く存在するグリコーゲンと基本構造が同じである植物由来の冷水可溶な貯蔵多糖類であり、α−１，４結合からなるグルコース鎖がα−１，６結合で高度に枝分かれした構造をしている。
そのため、皮膚外用剤において、その構造を活かし保湿剤として配合することが従来より提案されている（特開昭６２−１７８５０５、特開昭６３−２９０８０９）。
しかしながら、フィトグリコーゲンの線維芽細胞増殖効果に関しては未だ何ら報告されていない。
【０００３】
一方、線維芽細胞は、皮膚内の膠原線維、弾力線維、基質を産出し、皮膚の老化と密接な関係を有している。そのため、近年、皮膚外用剤の分野において、線維芽細胞の増殖効果を有する物質を配合し、皮膚の機能そのものを活性化して、皮膚の老化症状の改善を図る試みがなされている。このような物質としては、臓器由来の水溶性蛋白や牛胎盤エキス等が知られている。
【０００４】
【発明が解決しようとする課題】
しかしながら、臓器由来の水溶性蛋白は、蛋白質であるため、感作性で問題があり、一方、牛胎盤エキスにおいては、牛由来のものであるため、「狂牛病」の問題から安全性で疑問視されおり、安全性に優れた線維芽細胞増殖剤が切望されている。
そこで、本発明の目的は、安全性に優れた線維芽細胞増殖剤を提供することを目的とする。
【０００５】
【課題を解決するための手段】
本発明者らは、前記の目的を達成すべく安全性に優れた種々の多糖類について鋭意研究を重ねた結果、フィトグリコーゲンに線維芽細胞増殖効果を有することを見出し、本発明を完成するに至った。すなわち、本発明は、フィトグリコーゲンを有効成分として含有することを特徴とする線維芽細胞増殖剤、を提供するものである。
【０００６】
【発明の実施の形態】
以下、本発明を詳細に説明する。尚、本発明において「％」はすべて「重量％」である。
本発明において「フィトグリコーゲン」とは、前述したとおり、動物の肝臓や筋肉に多く存在するグリコーゲンと基本構造が同じである植物由来の冷水可溶な貯蔵多糖類である。フィトグリコーゲンの供給源としては、植物由来であれば特に限定するものでないが、例えば、トウモロコシ、大麦、米等の種子が挙げられる。その中でも、スイートコーンの種実は他の植物に比較し、フィトグリコーゲンを高濃度含有していることから、供給源として好ましい。
【０００７】
本発明で用いるフィトグリコーゲンの抽出・精製方法は特に制限はなく、任意の方法を採用することができる。一般的な調製方法を示すと、フィトグリコーゲンを含有する植物組織を粉砕等により抽出しやすい状態とした後、植物組織の固形分に対し３〜２０倍量の清水を加え水抽出し、デンプン、蛋白質、その他の不溶物を遠心分離等で除去する。得られた抽出液を加熱処理および／またはトリクロロ酢酸等で処理し蛋白質を除去した後、この処理液にメタノール、エタノール、アセトン等の有機溶剤を添加しフィトグリコーゲンを沈殿させる。尚、沈殿の際の有機溶剤の濃度は、溶剤により異なるが、例えば、メタノールやエタノールのようなアルコールの場合は６０容量％以上、アセトンの場合は５０容量％以上とするのが好ましい。この濃度より低い場合は、フィトグリコーゲンの一部あるいは全部が溶解した状態となるため、収率が低減し好ましくない。次に、回収した沈殿物をメタノール、エタノール、アセトン、ジエチルエーテル等の有機溶剤で洗浄した後、乾燥し粉末状のフィトグリコーゲンを得る。
【０００８】
本発明の線維芽細胞増殖剤は、上述の方法等により得られたフィトグリコーゲンをそのまま用いても良いし、さらに必要に応じ賦形剤等を加配しても良い。
【００１１】
次に、本発明を実施例・試験例に基づき、さらに詳細に説明する。尚、本発明は、これら実施例・試験例に制約されるものではない。
【実施例】
実施例１
新鮮なスイートコーン種実１ｋｇを粉砕機（商品名「ROBOT-COUPE CUTTING MIXER R-551 」、ティー・ケー・食品機械（株）扱い）で粉砕し、この粉砕物に１ｋｇの清水を加え混合後、２００メッシュストレーナーで濾過する。得られた濾液を遠心分離機（商品名「高速冷却遠心機 KR-20000S」、（株）久保田製作所製）で８５００ｒｐｍで５分間遠心分離し、デンプン、蛋白質、その他の不溶物を除去した。上清を濾紙で濾過後、９５℃で２０分間加熱し、冷却後、５０００ｒｐｍで５分間遠心分離し凝固した蛋白質を除去した。上清を４℃に冷却して、これに５％になるまでトリクロロ酢酸を加え、４℃で一晩放置したのち、５０００ｒｐｍで５分間遠心分離し沈殿物を除去し、上清を３倍量のメタノールに注加して生じた沈殿物を５０００ｒｐｍで５分間の遠心分離で集め、メタノール、エタノール、ジエチルエーテルで順次洗浄したのち真空乾燥し線維芽細胞増殖剤を得た。
得られた線維芽細胞増殖剤には、乾物中でフィトグリコーゲンを約９５％含有していた。
【００１３】
【試験例】
試験例１（線維芽細胞増殖試験）
＜試験方法＞
Ａ．線維芽細胞増殖剤のウェルへのコート
実施例１で得られた線維芽細胞増殖剤を蒸留水で溶解し、孔径０．２２μｍのメンブレンフィルターで濾過した後、浮遊培養用ウェル（商品名「浮遊培養用９６穴マルチプレート」、住友ベークライト（株）製）に線維芽細胞増殖剤のコート量が固形物として１００μｇ／cm2 となるように添加し、クリーンベンチ内で無菌的に風乾させた。
【００１４】
Ｂ．線維芽細胞の培養
ヒト真皮線維芽細胞（商品名「CryoNHDF-Neo、Strain No.4049」、三光純薬（株）製）を１０％ＦＢＳ（牛胎児血清）含有Ｄ−ＭＥＭ培地で１×１０4 セル／ｍｌとなるように分散し、線維芽細胞増殖剤をコートした各ウェルに１００μｌ添加した。次に、これを、３７℃、５％ＣＯ2 雰囲気下で培養し、３、５、６日目の細胞数を下記のクリスタルバイオレット法により把握した。尚、線維芽細胞増殖剤をコートしていないウェルを用い上記と同様な方法で培養したものを対照とした。
【００１５】
Ｃ．クリスタルバイオレット法
各ウェルに１０容量％ホルムアルデヒド含有ＰＢＳ（−）を添加し、３０分間静置して細胞を固定した後、培地を除去し、ＰＢＳ（−）で１回洗浄した。次に、染色液である０．４ｗ／ｖ％クリスタルバイオレット含有メタノールを各ウェルに５０μｌ添加し、３０分間静置して染色した後、染色液を除去し、蒸留水で洗浄し、２時間程度風乾し、５４５ｎｍにおける吸光度をウェルリーダーＳＫ−６０（（株）サイニクス製）で測定し、６ウェルの平均値を求めたところ、表１の結果が得られた。尚、吸光度０．１当たり約２．５×１０3 の細胞数に相当する。
【００１６】
【表１】
表１より、フィトグリコーゲンには線維芽細胞増殖効果を有していることが理解される。
【００２１】
【発明の効果】
以上述べたように本発明において、多糖類であるフィトグリコーゲンに線維芽細胞増殖効果を有することが認められる。これより、安全性に優れた線維芽細胞増殖剤を提供することができる。
【００２２】
【図面の簡単な説明】
【図１】試験例１における線維芽細胞の培養日数と細胞数を把握するクリスタルバイオレット法による吸光度との関係を示したものである。[0001]
BACKGROUND OF THE INVENTION
The present invention relates to a novel fibroblast growth agent as an active ingredient phytoglycogen.
[0002]
[Prior art]
Phytoglycogen is a plant-derived cold-water-soluble storage polysaccharide that has the same basic structure as glycogen that is present in a large amount in animal cells, particularly in the liver and muscle, and has a glucose chain composed of α-1,4 bonds. It has a highly branched structure with α-1,6 bonds.
For this reason, it has been conventionally proposed to use a skin moisturizer as a moisturizing agent by taking advantage of its structure (Japanese Patent Laid-Open Nos. 62-178505 and 63-290809).
However, nothing has been reported yet on the fibroblast proliferation effect of phytoglycogen.
[0003]
On the other hand, fibroblasts produce collagen fibers, elastic fibers, and substrates in the skin, and are closely related to skin aging. Therefore, in recent years, in the field of topical skin preparations, attempts have been made to improve the skin aging symptoms by blending a substance having a fibroblast proliferation effect and activating the skin function itself. As such substances, water-soluble proteins derived from organs, bovine placenta extract and the like are known.
[0004]
[Problems to be solved by the invention]
However, water-soluble protein derived from organs is a protein and therefore has a problem with sensitization. On the other hand, bovine placenta extract is derived from cattle and is therefore safe from the problem of “mad cow disease”. A fibroblast proliferating agent that is questioned and excellent in safety is eagerly desired.
Therefore, an object of the present invention is to provide a fibroblast proliferating agent excellent in safety.
[0005]
[Means for Solving the Problems]
As a result of intensive research on various polysaccharides excellent in safety to achieve the above-mentioned object, the present inventors have found that phytoglycogen has a fibroblast proliferation effect and complete the present invention. It came. That is, the present invention provides a fibroblast proliferating agent characterized by containing phytoglycogen as an active ingredient.
[0006]
DETAILED DESCRIPTION OF THE INVENTION
Hereinafter, the present invention will be described in detail. In the present invention, “%” is all “wt%”.
In the present invention, “phytoglycogen” is a plant-derived cold water-soluble storage polysaccharide having the same basic structure as glycogen that is abundant in the liver and muscle of animals as described above. The source of phytoglycogen is not particularly limited as long as it is derived from plants, and examples thereof include seeds such as corn, barley, and rice. Among them, sweet corn seeds are preferable as a supply source because they contain a higher concentration of phytoglycogen than other plants.
[0007]
The method for extracting and purifying phytoglycogen used in the present invention is not particularly limited, and any method can be adopted. When showing a general preparation method, after making the plant tissue containing phytoglycogen easy to be extracted by grinding or the like, 3 to 20 times the amount of fresh water is added to the solid content of the plant tissue and extracted with water, starch, Remove proteins and other insolubles by centrifugation. After the obtained extract is treated with heat and / or trichloroacetic acid to remove proteins, an organic solvent such as methanol, ethanol, acetone or the like is added to the treated solution to precipitate phytoglycogen. In addition, although the density | concentration of the organic solvent at the time of precipitation changes with solvents, it is preferable to set it as 60 volume% or more in the case of alcohol, such as methanol and ethanol, and 50 volume% or more in the case of acetone, for example. If the concentration is lower than this concentration, a part or all of phytoglycogen is dissolved, which is not preferable because the yield is reduced. Next, the collected precipitate is washed with an organic solvent such as methanol, ethanol, acetone, diethyl ether, and the like, and then dried to obtain powdery phytoglycogen.
[0008]
In the fibroblast proliferating agent of the present invention, phytoglycogen obtained by the above-described method or the like may be used as it is, and an excipient or the like may be added as necessary.
[0011]
Next, the present invention will be described in more detail based on examples and test examples. The present invention is not limited to these examples and test examples.
【Example】
Example 1
After pulverizing 1 kg of fresh sweet corn seeds with a pulverizer (trade name “ROBOT-COUPE CUTTING MIXER R-551”, treated by TK Foods Co., Ltd.) Filter through a 200 mesh strainer. The obtained filtrate was centrifuged at 8500 rpm for 5 minutes with a centrifuge (trade name “High Speed Cooling Centrifuge KR-20000S”, manufactured by Kubota Corporation) to remove starch, protein and other insoluble matters. The supernatant was filtered through filter paper, heated at 95 ° C. for 20 minutes, cooled, and centrifuged at 5000 rpm for 5 minutes to remove the coagulated protein. Cool the supernatant to 4 ° C, add trichloroacetic acid to 5%, leave it at 4 ° C overnight, centrifuge at 5000 rpm for 5 minutes to remove the precipitate, and add 3 times the amount of supernatant. The precipitate formed by pouring into methanol was collected by centrifugation at 5000 rpm for 5 minutes, washed successively with methanol, ethanol, and diethyl ether, and then vacuum dried to obtain a fibroblast proliferating agent.
The obtained fibroblast proliferating agent contained about 95% of phytoglycogen in the dry matter.
[0013]
[Test example]
Test Example 1 (Fibroblast proliferation test)
<Test method>
A. Coating of fibroblast proliferating agent on wells The fibroblast proliferating agent obtained in Example 1 was dissolved in distilled water, filtered through a membrane filter having a pore size of 0.22 μm, and then suspended in a well for suspension culture (trade name “floating” A 96-well multiplate for culture ”(manufactured by Sumitomo Bakelite Co., Ltd.) was added so that the coating amount of the fibroblast proliferating agent was 100 μg / cm 2 as a solid, and it was aseptically air-dried in a clean bench.
[0014]
B. Culture of fibroblasts Human dermal fibroblasts (trade name “CryoNHDF-Neo, Strain No. 4049”, manufactured by Sanko Junyaku Co., Ltd.) in D-MEM medium containing 10% FBS (fetal calf serum) 1 × 10 100 μl was added to each well which was dispersed to 4 cells / ml and coated with a fibroblast proliferating agent. Next, this was cultured at 37 ° C. in a 5% CO 2 atmosphere, and the number of cells on
[0015]
C. Crystal Violet Method PBS (−) containing 10% by volume of formaldehyde was added to each well and allowed to stand for 30 minutes to fix the cells. Then, the medium was removed and washed once with PBS (−). Next, 50 μl of 0.4 w / v% crystal violet-containing methanol, which is a staining solution, is added to each well and allowed to stand for 30 minutes for staining. Then, the staining solution is removed, washed with distilled water, and about 2 hours. After air drying, the absorbance at 545 nm was measured with a well reader SK-60 (manufactured by Sinix Co., Ltd.), and the average value of 6 wells was determined. The results shown in Table 1 were obtained. Incidentally, this corresponds to a cell number of about 2.5 × 10 3 per absorbance 0.1.
[0016]
[Table 1]
From Table 1, it is understood that phytoglycogen has a fibroblast proliferation effect.
[0021]
【The invention's effect】
As described above, in the present invention, it is recognized that phytoglycogen, which is a polysaccharide, has a fibroblast proliferation effect. Thus, a fibroblast proliferating agent excellent in safety can be provided.
[0022]
[Brief description of the drawings]
FIG. 1 shows the relationship between the number of days of fibroblast culture in Test Example 1 and the absorbance by the crystal violet method for grasping the number of cells.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP06128798A JP4762383B2 (en) | 1998-03-12 | 1998-03-12 | Fibroblast proliferator |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP06128798A JP4762383B2 (en) | 1998-03-12 | 1998-03-12 | Fibroblast proliferator |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH11255657A JPH11255657A (en) | 1999-09-21 |
| JP4762383B2 true JP4762383B2 (en) | 2011-08-31 |
Family
ID=13166843
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP06128798A Expired - Fee Related JP4762383B2 (en) | 1998-03-12 | 1998-03-12 | Fibroblast proliferator |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP4762383B2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10172946B2 (en) | 2013-04-26 | 2019-01-08 | Mirexus Biotechnologies Inc. | Monodisperse glycogen and phytoglycogen nanoparticles and use thereof as additives in cosmetics, pharmaceuticals, and food products |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPQ878600A0 (en) * | 2000-07-13 | 2000-08-03 | Gropep Pty Ltd | Compositions and methods for the treatment of intact skin |
| JP2004026766A (en) * | 2002-06-27 | 2004-01-29 | Kyoei Kagaku Kogyo Kk | Skin care preparation for external use |
| JP2005213185A (en) * | 2004-01-29 | 2005-08-11 | Bizen Chemical Co Ltd | Energy-supplementary and anti-fatigue food and beverage |
| JP4853994B2 (en) * | 2004-03-31 | 2012-01-11 | 昭和電工株式会社 | Topical skin preparation |
| ES2293753B1 (en) * | 2004-04-28 | 2009-03-16 | Lipotec, S.A. | USE OF XIKVAV PEPTIDES IN PREPARATION OF COSMETIC COMPOSITIONS TO IMPROVE SKIN FIRMING THROUGH THE INCREASE OF CELLULAR ADHESION. |
| ES2469796T3 (en) * | 2008-02-01 | 2014-06-20 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | Cosmetic composition comprising glycogen for a velvety cutaneous application |
| JP2012062273A (en) * | 2010-09-15 | 2012-03-29 | Ezaki Glico Co Ltd | Glycogen-containing agent for promoting production of hyaluronic acid and elastin |
| US10918124B2 (en) * | 2011-08-02 | 2021-02-16 | Purdue Research Foundation | Extraction, purification, and processing of phytoglycogen |
| JP2016023155A (en) * | 2014-07-18 | 2016-02-08 | 江崎グリコ株式会社 | Ceramide production promoter and skin external preparation |
-
1998
- 1998-03-12 JP JP06128798A patent/JP4762383B2/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10172946B2 (en) | 2013-04-26 | 2019-01-08 | Mirexus Biotechnologies Inc. | Monodisperse glycogen and phytoglycogen nanoparticles and use thereof as additives in cosmetics, pharmaceuticals, and food products |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH11255657A (en) | 1999-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Stacey | The chemistry of mucopolysaccharides and mucoproteins | |
| JP4762383B2 (en) | Fibroblast proliferator | |
| CN102821750B (en) | Preparation, its purposes and its production for being used to treat skin aging, inflammation and scar caused by vitro culture from the Ci Agan tree cells of induction dedifferente, non- | |
| US12280136B2 (en) | Compositions containing exosomes from animal placenta, methods for producing the same and uses thereof | |
| CN107531775A (en) | The purposes of collagen water decomposition thing and collagen water decomposition thing rich in collagen tripeptide | |
| CN113018225B (en) | Low-irritation facial cleanser | |
| Steinert et al. | Large circular mitochondrial DNA in Crithidia luciliae | |
| US4421746A (en) | Process for producing interferon inducers | |
| CN112708652B (en) | Avocado oil-in-water liquid state fermentation product and preparation method and application thereof | |
| CN104745664A (en) | Preparation process of animal placenta extract | |
| EP0237398B1 (en) | Use of biologically active polypeptides and compositions containing them | |
| JP2521853B2 (en) | Cosmetics | |
| KR19980703075A (en) | Materials extracted from dicthiotals, methods for their preparation and compositions containing them | |
| JPH11501055A (en) | Novel use of compositions containing nacres | |
| CN104087640A (en) | Cornua cervi pantotrichum polypeptide serial extraction method beneficial to skin or mucosa absorption | |
| JP2011190217A (en) | Human epidermal cell growth promoter, and skin care composition for external use and cosmetic each containing the same | |
| CN109627323A (en) | Snakeskin collagen peptide and its preparation and application | |
| Polatnick et al. | Comparison of collagen preparations from beef cornea and sclera | |
| CN110393697A (en) | A kind of jelly peptide essence and preparation method thereof | |
| CN113908088A (en) | Liquid shampoo | |
| CN102895165B (en) | Composite active matters of mask and preparation method of composite active matters | |
| JPH08507506A (en) | Collagenase activity inhibitors and cosmetic compositions containing such inhibitors | |
| CN118615219B (en) | Skin anti-aging complex containing lotus stamen extract and preparation method thereof | |
| TW202116346A (en) | Composition for acceleration of collagen production | |
| JPS63216432A (en) | Yogurt |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040910 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080422 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080620 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080715 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080904 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081016 |
|
| A911 | Transfer of reconsideration by examiner before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20081021 |
|
| A912 | Removal of reconsideration by examiner before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20081114 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110608 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140617 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |